The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation

References

• European Heart Rhythm Association, European Association for Cardio-Thoracic SurgeryCammAJGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J201031192369242920802247
   PubMed Web of Science ®Google Scholar
• FusterVRydénLECannomDSACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyCirculation20061147e257e35416908781
   PubMed Web of Science ®Google Scholar
• WannLSCurtisABJanuaryCT2011ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation2011123110412321173346
   PubMed Web of Science ®Google Scholar
• PsatyBMManolioTAKullerLHIncidence of and risk factors for atrial fibrillation in older adultsCirculation1997967245524619337224
   PubMed Web of Science ®Google Scholar
• BenjaminEJWolfPAD’AgostinoRBSilbershatzHKannelWBLevyDImpact of atrial fibrillation on the risk of death: the Framingham Heart StudyCirculation199898109469529737513
   PubMed Web of Science ®Google Scholar
• KomatsuTTachibanaHSatoYOzawaMKunugidaFNakamuraMEfficacy of antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term cardiovascular prognosis in patients with asymptomatic paroxysmal atrial fibrillationInt Heart J20105129810420379042
   PubMed Web of Science ®Google Scholar
• DobrevDNattelSNew antiarrhythmic drugs for treatment of atrial fibrillationLancet201037597211212122320334907
   PubMed Web of Science ®Google Scholar
• NattelSNew ideas about atrial fibrillation 50 years onNature2002415686821922611805846
   PubMed Web of Science ®Google Scholar
• RavensUNovel pharmacological approaches for antiarrhythmic therapyNaunyn Schmiedebergs Arch Pharmacol2010381318719320082192
   PubMed Web of Science ®Google Scholar
• ChoHCMarbánEBiological therapies for cardiac arrhythmias: can genes and cells replace drugs and devices?Circ Res2010106467468520203316
   PubMed Web of Science ®Google Scholar
• Hodgson-ZingmanDMKarstMLZingmanLVAtrial natriuretic peptide frameshift mutation in familial atrial fibrillationN Engl J Med2008359215816518614783
   PubMed Web of Science ®Google Scholar
• OlsonTMMichelsVVBallewJDSodium channel mutations and susceptibility to heart failure and atrial fibrillationJAMA2005293444745415671429
   PubMed Web of Science ®Google Scholar
• ChenYHXuSJBendahhouSKCNQ1 gain-of-function mutation in familial atrial fibrillationScience2003299560425125412522251
   PubMed Web of Science ®Google Scholar
• YangYXiaMJinQIdentification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillationAm J Hum Genet200475589990515368194
   PubMed Web of Science ®Google Scholar
• GudbjartssonDFHolmHGretarsdottirSA sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic strokeNat Genet200941887687819597491
   PubMed Web of Science ®Google Scholar
• BenjaminEJRiceKMArkingDEVariants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestryNat Genet200941887988119597492
   PubMed Web of Science ®Google Scholar
• EllinorPTLunettaKLGlazerNLCommon variants in KCNN3 are associated with lone atrial fibrillationNat Genet201042324024420173747
   PubMed Web of Science ®Google Scholar
• HaissaguerreMJaisPShahDCSpontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veinsN Engl J Med1998339106596669725923
   PubMed Web of Science ®Google Scholar
• AllessieMABonkeFISchopmanFJCircus movement in rabbit atrial muscle as a mechanism of tachycardia III. The “leading circle” concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacleCirc Res1977411918862147
   PubMed Web of Science ®Google Scholar
• DavidenkoJMPertsovAVSalomonszRBaxterWJalifeJStationary and drifting spiral waves of excitation in isolated cardiac muscleNature199235563583493511731248
   PubMed Web of Science ®Google Scholar
• PertsovAMDavidenkoJMSalomonszRBaxterWTJalifeJSpiral waves of excitation underlie reentrant activity in isolated cardiac muscleCirc Res19937236316508431989
   PubMed Web of Science ®Google Scholar
• VarroABiliczkiPLostNViragLHalaOPappJGPharmacology of potassium channel blockersPappJGStraubMZieglerDAtrial Fibrillation: New Therapeutic ConceptsAmsterdamIOS Press/Ohmsa20032739
   Google Scholar
• NattelSMaguyALe BouterSYehYHArrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillationPhysiol Rev200787242545617429037
   PubMed Web of Science ®Google Scholar
• RavensUCerbaiERole of potassium currents in cardiac arrhythmiasEuropace200810101133113718653669
   PubMed Web of Science ®Google Scholar
• ThomasDKarleCAKiehnJThe cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applicationsCurr Pharm Des200612182271228316787254
   PubMed Web of Science ®Google Scholar
• AllessieMAusmaJSchottenUElectrical, contractile and structural remodeling during atrial fibrillationCardiovasc Res200254223024612062329
   PubMed Web of Science ®Google Scholar
• WorkmanAJCardiac adrenergic control and atrial fibrillationNaunyn Schmiedebergs Arch Pharmacol2010381323524919960186
   PubMed Web of Science ®Google Scholar
• JonsCRaatikainenPGangUJAutonomic dysfunction and new-onset atrial fibrillation in patients with left ventricular systolic dysfunction after acute myocardial infarction: a CARISMA substudyJ Cardiovasc Electrophysiol201021998399020487120
   PubMed Web of Science ®Google Scholar
• ShengXScherlagBJYuLPrevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulationJ Am Coll Cardiol201157556357121272747
   PubMed Web of Science ®Google Scholar
• CarlssonJMiketicSWindelerJRandomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) studyJ Am Coll Cardiol20034151690169612767648
   PubMed Web of Science ®Google Scholar
• HohnloserSHKuckKHLilienthalJRhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trialLancet200035692441789179411117910
   PubMed Web of Science ®Google Scholar
• Van GelderICHagensVEBoskerHAA comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillationN Engl J Med2002347231834184012466507
   PubMed Web of Science ®Google Scholar
• WyseDGWaldoALDiMarcoJPAtrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillationN Engl J Med2002347121825183312466506
   PubMed Web of Science ®Google Scholar
• OpolskiGRate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) StudyChest2004126247648615302734
   PubMed Web of Science ®Google Scholar
• WolbretteDGonzalezMSamiiSBanchsJPenny-PetersonENaccarelliGDronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacyVasc Health Risk Manag2010651752320730068
   PubMedGoogle Scholar
• ThomasDKathoferSZhangWAcute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channelsBr J Pharmacol20031405996100214517175
   PubMed Web of Science ®Google Scholar
• KathoferSThomasDKarleCAThe novel antiarrhythmic drug dronedarone: comparison with amiodaroneCardiovasc Drug Rev200523321723016252015
   PubMed Web of Science ®Google Scholar
• SchweizerPABeckerRKatusHAThomasDDronedarone: current evidence for its safety and efficacy in the management of atrial fibrillationDrug Des Devel Ther201152739
   PubMed Web of Science ®Google Scholar
• HohnloserSHCrijnsHJvan EickelsMEffect of dronedarone on cardiovascular events in atrial fibrillationN Engl J Med2009360766867819213680
   PubMed Web of Science ®Google Scholar
• FDA.gov [homepage on the internet]RockvilleUS Food and Drug Administration FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq) [updated January 20, 2011]. http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm. Accessed February 5, 2011.
   Google Scholar
• DobrevDHamadBKirkpatrickPVernakalantNat Rev Drug Discov201091291591621119728
   PubMed Web of Science ®Google Scholar
• FedidaDOrthPMChenJYThe mechanism of atrial antiarrhythmic action of RSD1235J Cardiovasc Electrophysiol200516111227123816302909
   PubMed Web of Science ®Google Scholar
• DorianPPinterAMangatIKorleyVCvitkovicSSBeatchGNThe effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humansJ Cardiovasc Pharmacol2007501354017666913
   PubMed Web of Science ®Google Scholar
• CammAJCapucciAHohnloserSHA randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillationJ Am Coll Cardiol201157331332121232669
   PubMed Web of Science ®Google Scholar
• GiertenJFickerEBloehsRRegulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genisteinBr J Pharmacol200815481680169018516069
   PubMed Web of Science ®Google Scholar
• GiertenJFickerEBloehsRThe human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodaroneNaunyn Schmiedebergs Arch Pharmacol2010381326127019777211
   PubMed Web of Science ®Google Scholar
• DheinSHagenAJozwiakJImproving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptidesNaunyn Schmiedebergs Arch Pharmacol2010381322123419943035
   PubMed Web of Science ®Google Scholar
• DobrevDAtrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug targetNaunyn Schmiedebergs Arch Pharmacol2010381319520619784635
   PubMed Web of Science ®Google Scholar
• JaïsPShahDCHaïssaguerreMEfficacy and safety of septal and left-atrial linear ablation for atrial fibrillationAm J Cardiol1999849A139R146R
   PubMed Web of Science ®Google Scholar
• PapponeCRosanioSOretoGCircumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillationCirculation2000102212619262811085966
   PubMed Web of Science ®Google Scholar
• NademaneeKMcKenzieJKosarEA new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrateJ Am Coll Cardiol200443112044205315172410
   PubMed Web of Science ®Google Scholar
• PokushalovERomanovAArtyomenkoSGanglionated plexi ablation for longstanding persistent atrial fibrillationEuropace201012334234620173210
   PubMed Web of Science ®Google Scholar
• GaitaFCaponiDScaglioneMLong-term clinical results of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillationCirc Arrhythm Electrophysiol20081426927519808418
   PubMed Web of Science ®Google Scholar
• TakahashiACatheter ablation is established as a treatment option for atrial fibrillation – is catheter ablation established as a treatment option of atrial fibrillation? (Pro)Circ J20107491972197720716832
   PubMed Web of Science ®Google Scholar
• OuyangFTilzRChunJLong-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-upCirculation2010122232368237721098450
   PubMed Web of Science ®Google Scholar
• JaïsPPackerDLAblation vs drug use for atrial fibrillationEur Heart J Suppl20079Suppl GG26G34
   Web of Science ®Google Scholar
• HartRGBenaventeOMcBrideRPearceLAAntithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysisAnn Intern Med1999131749250110507957
   PubMed Web of Science ®Google Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA2001285222864287011401607
   PubMed Web of Science ®Google Scholar
• GageBFvan WalravenCPearceLSelecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirinCirculation2004110162287229215477396
   PubMed Web of Science ®Google Scholar
• LipGYNieuwlaatRPistersRLaneDACrijnsHJRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillationChest2010137226327219762550
   PubMed Web of Science ®Google Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar
• GageBFYanYMilliganPEWatermanADCulverhouseRRichMWClinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)Am Heart J2006151371371916504638
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• EikelboomJWO’DonnellMYusufSRationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatmentAm Heart J20101593348353.e120211294
   PubMed Web of Science ®Google Scholar
• LopesRDAlexanderJHAl-KhatibSMApixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleAm Heart J2010159333133920211292
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study InvestigatorsRivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF studyAm Heart J20101593340347.e120211293
   PubMed Web of Science ®Google Scholar
• DawsonAGAsopaSDunningJShould patients undergoing cardiac surgery with AF have left atrial appendage exclusion?Interact Cardiovasc Thorac Surg201010230631119942634
   PubMed Web of Science ®Google Scholar
• KanderianASGillinovAMPetterssonGBBlackstoneEKleinALSuccess of surgical left atrial appendage closure: assessment by transesophageal echocardiographyJ Am Coll Cardiol2008521192492918772063
   PubMedGoogle Scholar
• OstermayerSHReismanMKramerPHPercutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trialsJ Am Coll Cardiol200546191415992628
   PubMed Web of Science ®Google Scholar
• SickPBSchulerGHauptmannKEInitial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillationJ Am Coll Cardiol200749131490149517397680
   PubMed Web of Science ®Google Scholar
• HolmesDRReddyVYTuriZGPercutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trialLancet2009374968953454219683639
   PubMed Web of Science ®Google Scholar
• BlockPCBursteinSCasalePNPercutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) StudyJACC Cardiovasc Interv20092759460019628179
   PubMed Web of Science ®Google Scholar
• MarbánECardiac channelopathiesNature2002415686821321811805845
   PubMed Web of Science ®Google Scholar
• DonahueJKHeldmanAWFraserHFocal modification of electrical conduction in the heart by viral gene transferNat Med20006121395139811100126
   PubMed Web of Science ®Google Scholar
• BauerAMcDonaldADNasirKInhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillationCirculation2004110193115312015505099
   PubMed Web of Science ®Google Scholar
• AmitGKikuchiKGreenerIDYangLNovackVDonahueJKSelective molecular potassium channel blockade prevents atrial fibrillationCirculation2010121212263227020479154
   PubMed Web of Science ®Google Scholar